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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).SUMMARYPelizaeus-Merzbacher disease (PMD) is a form of X-linked leukodystrophy caused by mutations in the proteolipid protein 1 (PLP1) gene.
Although PLP1 proteins with missense mutations have been shown to accumulate in the rough endoplasmic reticulum (ER) in disease
model animals and cell lines transfected with mutant PLP1 genes, the exact pathogenetic mechanism of PMD has not previously been
clarified. In this study, we established induced pluripotent stem cells (iPSCs) from two PMD patients carrying missense mutation and
differentiated them into oligodendrocytes in vitro. In the PMD iPSC-derived oligodendrocytes, mislocalization of mutant PLP1 proteins
to the ER and an association between increased susceptibility to ER stress and increased numbers of apoptotic oligodendrocytes were
observed. Moreover, electron microscopic analysis demonstrated drastically reduced myelin formation accompanied by abnormal ER
morphology. Thus, this study demonstrates the involvement of ER stress in pathogenic dysmyelination in the oligodendrocytes of
PMD patients with the PLP1 missense mutation.INTRODUCTION
Analysis of differentiated cells from disease-specific, hu-
man induced pluripotent stem cells (iPSCs) enables the
construction of pathological models using the patients’
own cells. Such analyses are particularly useful for the
study of neurodegenerative disorders because it is difficult
to collect brain-tissue samples from these patients.
Pelizaeus-Merzbacher disease (PMD) is a dysmyelinating
disorder of the CNS that is usually observed during child-
hood. PMD is classified into two subtypes: the classical and
connatal forms. In the classical form, patients usually
show a delay in psychomotor development within the first
year of life but exhibit relatively slow disease progression
over the first decade. In contrast, in the connatal form,
patients generally show arrested congenital psychomotor
development and exhibit a progressive disease course
with severe neurological impairment. The degree of dys-
myelination has been shown to correlate well with the
clinical severity of PMD (Seitelberger, 1995). The proteolipid
protein 1 (PLP1) gene has been identified as a causative
gene for PMD. PLP1 is a transmembrane protein that is648 Stem Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authorsabundantly expressed in compact myelin in oligodendro-
cytes (OLs) and plays a structural role in the formation and
maintenance of myelin sheaths (Gow et al., 1997; Mikosh-
iba et al., 1991). Three distinct types of PLP1 mutation
have been reported to date: point mutations, duplications,
and deletions. Missense mutations in the PLP1 gene
account for 30% of the genetic abnormalities found in
PMD patients and are responsible for most of connatal
cases. Based on analyses using cell lines transfected with
mutant PLP1 genes (Gow and Lazzarini, 1996) or a mouse
model of PMD (the msd mouse; Gow et al., 1998), the
underlying pathogenesis in most patients with missense
mutations is thought to involve the accumulation of mis-
folded mutant PLP1 proteins in the rough endoplasmic
reticulum (ER) (Southwood et al., 2002) and the induction
of ER stress, resulting in activation of the unfolded protein
response (UPR). Although UPR attenuates general transla-
tion to reduce the protein load into ER and increase
expression of chaperone proteins to facilitate protein
folding, excessive levels of unfolded proteins have been
shown to activate apoptotic pathway of UPR to eliminate
damaged OLs.
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conventional cellular and animal PMD models, it has
not been possible to examine the actual correlation
between the known molecular pathogenesis and cell bio-
logical phenotypes, including abnormalities in OL differ-
entiation, myelination, and cell death. In addition, those
previous results were obtained through analyses using
nonhuman models, non-patient-derived cells, or nonoli-
godendrocyte models, and it is unknown whether the re-
sults obtained in those models are applicable to human
patients. Although the establishment of iPSCs from a
PMD patient with partial duplication of PLP1 gene has
been reported, those iPSCs were not differentiated into
oligodendrocytes for disease modeling (Shimojima et al.,
2012). Thus, in the present study, we focused on the path-
ologic effects of PLP1 missense mutations and established
patient-specific iPSCs from two PMD patients with
different mutation sites and different levels of clinical
severity.
We differentiated the iPSCs into OL lineage cells and
examined thepathogenic changes in thePMD iPSC-derived
OLs. We confirmed the accumulation and mislocalization
ofmutant PLP1 proteins to the ER, a high level of stress sus-
ceptibility, and increased apoptosis in PMD iPSC-derived
OLs. In addition, through transmission electron micro-
scopic analysis, we verified decreases in the frequency of
myelin formation and the thickness of the myelin sheath
compared with control cells. More importantly, we also
demonstrated that these pathogenic changes observed in
iPSC-derived OLs were consistent with the different levels
of clinical severity between the two PMD patients. Thus,
this report describes the modeling of human PMD with
PLP1 missense mutations using patient-specific, iPSC-
derived OLs. These results have demonstrated the useful-
ness of iPSC-derived OLs for the analysis of the pathogenic
processes inhumandysmyelinatingneurological disorders.RESULTS
Clinical Features of PMD Patients
We established iPSCs from two patients with point muta-
tions in the transmembrane domain (patient 1: PMD1)
and extracellular domain (patient 2: PMD2) of the PLP1
gene (Figure 1C). PMD1was a 1-year-oldmalewith the con-
natal form of PMD. He was diagnosed with PMD at the age
of 4 months, when he was found to exhibit poor head con-
trol and nystagmus and was unable to follow objects. He
showed poor feeding and was fed through a gastrostomy
tube from the age of 21 months. Psychomotor develop-
ment was not observed, even at the age of 5 years. MRI of
the patient’s brain revealed mild and diffuse atrophy,
dilatation of the ventricles, and diffuse high-intensity sig-Stenals in the white matter of the cerebrum and brainstem
in a T2-weighted image (T2WI) (Figure 1A). A direct
sequencing analysis of genomic DNA from the patient’s
leukocytes showed a novel missense mutation, c.757 T >
A (p.Ser253Thr), in exon 6 of the PLP1 gene (Figure 1B).
This amino acid change has not been previously reported,
but different type of mutation at this same site, Ser253Phe,
has been reported in other patients with the connatal form
of PMD (Hodes et al., 1998). This change was not identified
in more than 200 normal individuals; thus, it was consid-
ered to be a causative mutation for PMD.
Patient 2 (PMD2) was a 20-year-old male with the clas-
sical form of PMD. He was diagnosed with PMD at the
age of 3 months, when he was found to display poor
head control and nystagmus. Spastic quadriparesis was
evident at 4 years of age, with choreoathetotic movements
beginning at the age of 8–10 years. He appeared alert and
attentive and was nonverbal but exhibited guttural vocali-
zations. A missense mutation, c.643 C > T (p.Pro215Ser),
was identified in exon 5 of the PLP1 gene, which has
been reported previously (Gencic et al., 1989).
Establishment and Characterization of iPSCs Derived
from PMD Patients
Human iPSCs were established via the retroviral transduc-
tion of four transcription factors (SOX2, OCT4, KLF4, and
c-MYC) into dermal fibroblasts (Takahashi et al., 2007). A
total of 52 and 34 iPSC clones were established from
PMD1 and PMD2 samples, respectively. The established
iPSC clones were evaluated based on the typical
morphology of colonies similar to human embryonic
stem cells (ESCs), as well as the expression of pluripotent
markers via immunocytochemistry (NANOG and OCT4;
Figure 1D), silencing of retroviral transgenes through quan-
titative RT-PCR (Figure 1E), and efficient differentiation
into neural cells via embryoid body (EB) formation. We
finally selected three clones each for PMD1 (1-7, 1-15,
and 1-27) and PMD2 (2-6, 2-10, and 2-22) for further
analyses. The differentiation potentials of these selected
iPSC clones were confirmed through teratoma formation
assays (ectoderm: neural rosettes and pigmented epithe-
lium, endoderm: goblet cells, and mesoderm: bones and
cartilage; Figure 1F). Moreover, the mutations in the PLP1
gene (PMD1 [c.757 T > A] and PMD2 [c.643 C > T]) were
confirmed in human dermal fibroblasts (HDFs) and all
of the selected iPSC clones via pyrosequencing analysis
(Figure 1G).
Regarding the control iPSCs, we used age-matched con-
trol iPSCs established from 8-month-old (TIG121) and
16-year-old (WD39) healthy individuals, corresponding
to the PMD-iPSCs established from 1-year-old and 20-
year-old patients, respectively, as well as 201B7, which is
a widely used control iPSC clone.m Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authors 649
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Modeling PMD by iPSC-Derived OligodendrocytesBoth Control and PMD iPSCs Induce Oligodendrocyte
Lineage Cells In Vitro
Based on the previously reported methods for inducing
OLs from human ESCs and iPSCs (Hu et al., 2009; Izrael
et al., 2007; Kang et al., 2007), we established our own cul-
ture protocol to induce OLs bymodifying previously estab-
lished protocols for efficiently differentiating human ESCs
and iPSCs into neural stem/progenitor cells (NS/PCs) as
neurospheres through EB formation (Nori et al., 2011;
Okada et al., 2008). First, dorsomorphin (a bonemorphoge-
netic protein signal inhibitor), SB431542 (a transforming
growth factor b [TGF-b] receptor inhibitor), and BIO (a
GSK3 inhibitor) were added during the early phase of EB
formation to facilitate differentiation into NS/PCs more
efficiently. Quantitative RT-PCR analysis of the expression
of the NS/PC marker SOX1 in EBs revealed a significantly
higher induction efficiency of NS/PCs in our protocol
with DSB (DSB: dorsomorphin, SB431542, and BIO)
compared with those in our previously established
methods (control, DSB) or those in the previously re-
ported dual Smad inhibition with DS (Figure 2B). We also
added retinoic acid for caudalization and purmorphamine
(Sonic hedgehog agonist) for ventralization during EB
formation until EB dissociation. Then, the dissociated
EBs were cultured in suspension to form neurospheres in
proliferation medium supplemented with factors that
promote the commitment and proliferation of OL lineage
cells (Shimada et al., 2012). For adherent differentiation,
neurospheres were cultured in differentiation medium
supplemented with factors that promote the commitment
of OL lineage cells as indicated in the Experimental Proce-
dures (Figure 2A). From the quantitative RT-PCR analysis
in this protocol, the pluripotent marker (NANOG) was
notably downregulated in the EB stage, and other lineage
markers (mesodermal and endodermal markers, such as
BRACHYURY and SOX17) were not detected in any stage.Figure 1. Features of the PMD Patients and Characterization of iP
(A) MRI images of the brains of patient PMD1 (right) and an age-match
the ventricles (open arrow), and diffuse high-intensity signals in t
images; T2WI, T2-weighted images.
(B) Direct sequencing analysis of genomic DNA from PMD1’s leukocytes
the PLP1 gene.
(C) Schematic representation of the mutation sites in PMD1 and PMD
(D) Representative morphology of iPSC colonies (above) and immunoc
The scale bars represent 200 mm.
(E) Quantitative RT-PCR analysis of the expression of retroviral transge
copy numbers for each transgene divided by those for b-actin.
(F) Representative H&E staining of teratomas derived from establis
undifferentiated iPSCs into the testes of NOD/SCID mice. Open arro
goblet cells. Arrow, bones. Open arrowhead, cartilage. The scale bars
(G) Representative pyrosequencing analysis of the mutations in the
observed in the patients’ fibroblasts (PMD1, 757 T > A; PMD2, 643 C
SteThe NS/PC marker (SOX1) was upregulated in the EB and
neurosphere stages and gradually downregulated after
adherent differentiation (differentiation stage; Figure 2C).
The expression profiles were similar between the control,
PMD1, and PMD2 iPSCs (Figure S1A available online).
To reveal the differentiation potentials of neurospheres,
we performed immunocytochemistry of differentiated
neurospheres for markers of neurons (bIII tubulin), astro-
cytes (GFAP), and oligodendrocytes (O4; Figures 2E and
2F) and a time course analysis of the expression levels
of neuronal and glial markers through quantitative RT-
PCR (Figure 2D). The expression profiles were similar
between the control and PMD1 and PMD2 cells (Fig-
ure S1B). Based on these analyses, we confirmed the
differentiation potentials of the iPSCs into three neural
lineage cells and the reproducibility of our differentiation
protocol. Regarding the differentiation potentials of
OL lineage cells, all PMD-iPSCs and control iPSCs were
able to induce platelet-derived growth factor receptor a
(PDGFRa)+-OL progenitor cells (OPCs), O4+-immature
OLs (immature OLs), and myelin basic protein (MBP)+-
mature OLs (mature OLs) with typical morphologies (Fig-
ure 3B). OPCs were also positive for NG2 (Figure 3A). In
contrast, myelin protein zero (MPZ)-positive cells, a major
structural protein of peripheral myelin, could not be de-
tected, indicating that these cells were oligodendrocytes,
but not schwann cells.
After 55–70 days in vitro (DIV), OPCs were observed
in 86.3% of the colonies of control cells and 95.1% and
90.5% of the colonies of PMD1 and PMD2 cells, respec-
tively. At 70–85 DIV, immature OLs were observed in
77.8% of control colonies and 93.8% and 93.8% of the col-
onies of PMD1 and PMD2 cells, respectively. At 80–95 DIV,
mature OLs were observed in 74.9% of the colonies of con-
trol cells and 93.8% and 89.2% of the colonies of PMD1
and PMD2 cells, respectively (Figure 3C). No significantSCs
ed control (left). Mild and diffuse atrophy of the brain, dilatation of
he white matter (open arrowhead) are shown. T1WI, T1-weighted
showed a missense mutation c.757 T > A (p.Ser253Thr) in exon 6 of
2.
hemical analysis of pluripotent markers, NANOG and OCT4 (below).
nes in established PMD iPSC clones. Data are presented as the mRNA
hed PMD iPSC clones. Teratomas were formed via the injection of
w, neural rosettes. Arrowhead, pigmented epitheliums. Asterisks,
represent 200 mm.
PLP1 gene in fibroblasts and iPSCs. Identical mutations to those
> T) were confirmed in all the iPSC clones.
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Figure 2. Differentiation Potential of Human iPSCs
(A) Schematic presentation of the protocols for OL differentiation from hiPSCs. DSB, dorsomorphine (D), SB431542 (S), and BIO (B); RA,
retinoic acid; NS, neurospheres.
(B) Quantitative RT-PCR analysis of SOX1 expression in EBs, suggesting a significantly higher induction efficiency of NS/PCs in EBs in our
protocol with DSB (DSB: dorsomorphin, SB431542, and BIO) compared with those in our previously established methods (control, DSB)
or those in the previously reported method with dual Smad inhibition (DS) (n = 3, mean ± SEM; independent experiments; *p < 0.05; **p <
0.01; t test).
(C) Quantitative RT-PCR analysis of the expression of cell-type-specific markers at each differentiation stage. NANOG (a pluripotent marker)
was readily downregulated in the EB stage. Other lineage markers (mesodermal and endodermal markers, such as BRACHYURY and SOX17)
were not detected in any stage. SOX1was upregulated in EB and neurosphere stage in control iPSC clones (201B7, WD39, and TIG121; n = 3;
mean ± SEM; independent experiments).
(D) Quantitative RT-PCR analysis of differentiated neurospheres for the markers of neurons (bIII tubulin), astrocytes (GFAP), and
oligodendrocytes (CNP) in control iPSC clones (201B7, WD39, and TIG121; n = 3; mean ± SEM; independent experiments).
(legend continued on next page)
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Modeling PMD by iPSC-Derived Oligodendrocytesdifferences were detected in either control or PMD with re-
gard to OL lineage differentiation efficiency.
To examine the proportion of immature and mature OL
lineage cells, we performed immunocytochemistry for
OLIG2, PDGFRa, andMBP after 2 or 4weeks differentiation
of control-iPSC-derived second neurospheres containing
more than 40 OLIG2-positive cells and counted the num-
ber of marker-positive cells (Figures 3D and 3E). After 2
and 4 weeks of differentiation, OLIG2+ and PDGFRa+
OPCs were abundantly observed. After 4 weeks of differen-
tiation, small numbers of MBP+ mature OLs appeared.Involvement of ER Stress in PMD
Previous in vitro transfection studies in nonglial cells have
indicated that various PLP1 mutants accumulate in the
ER immediately after translation, in contrast to the distri-
bution of wild-type PLP1 at the plasma membrane (Gow
et al., 1994; Gow and Lazzarini, 1996; Thomson et al.,
1997). Therefore, we next examined the expression of
PLP1 proteins via immunocytochemistry. When stained
with anti-PLP1 andMBP antibodies, themembrane protein
PLP1was observed to be dispersed into the processes of OLs
and to colocalize with MBP in control iPSC-derived mature
OLs. However, in PMD1 and PMD2 iPSC-derived mature
OLs, PLP1 protein staining was not observed in the OL
processes; instead, PLP1 protein staining localized to the
perinuclear cytoplasm (Figure 4A). Thus, we also performed
staining for the ER marker KDEL and found that the mislo-
calized PLP1 proteins colocalized with KDEL (Figures 4A
and 4B). All of the control iPSC-derived OLs showed stain-
ing for PLP1 proteins in the processes of mature OLs,
whereas all of the PMD iPSC-derived mature OLs only ex-
hibited PLP1 protein localization in the ER. These results
suggest that mutant PLP1 proteins accumulated in the
ER and triggered ER stress in mature OLs derived from
PMD-iPSCs.
We next examined the expression of ER stress markers
in OLs. O4+ cells were isolated from both the PMD and
control iPSC-derived differentiated cells 4 weeks after the
attachment of the second neurospheres via magnetic-acti-
vated cell sorting (MACS) using an anti-O4 antibody. The
purified O4+ cells underwent quantitative RT-PCR to deter-
mine the expression of ER stress markers (BIP, CHOP, and
spliced XBP1). No significant differences were detected be-
tween the control and PMD iPSC-derivedOLs regarding the
expression of ER stress markers under default conditions
(Figure 4C). Therefore, we next examined the susceptibility(E) Representative low-magnification images of the immunocytochem
GFAP; oligodendrocytes: O4). The scale bar represents 100 mm.
(F) Quantitative analysis of the percentages of three neural lineage
spheres (n = 9; mean ± SEM; independent experiments).
Steof the iPSC-derived OLs to the extrinsic ER stress induced
by treatment with a low concentration of tunicamycin
50 nM for 6 hr (known as an ER-stress inducer). The results
showed that the expression of all ER-stress markers was
significantly increased in tunicamycin-treated O4+ cells
relative to untreated O4+ cells in PMD1 (Figure 4D). This
result suggested that a higher susceptibility to ER stress
was observed in PMD1 iPSC-derived OLs than in those
derived from control and PMD2 iPSCs.
We next treated the iPSC-derived OLs with a higher con-
centration of tunicamycin 100 nM for 6 hr and examined
the expression levels of ER stress markers. PMD2 iPSC-
derived OLs showed significantly higher expression levels
of spliced XBP1, the most sensitive ER stress marker, than
control iPSC-derived OLs (Figure 4E). No significant differ-
ences were detected in the expression levels of BIP and
CHOP between control and PMD2. Taken together, these
results suggest that ER stress is involved in the pathogenesis
of the PMD patients with PLP1 missense mutations, and a
higher susceptibility to ER stress was observed in PMD1
iPSC-derived OLs than in those derived from PMD2, which
is consistent with themore severe phenotypes of the PMD1
patient compared with the PMD2 patient.Increased Apoptosis Is Observed in PMD iPSC-Derived
Oligodendrocytes
In addition to their susceptibility toER stress, thePMDiPSC-
derived OLs showed significant morphological differences,
as revealed by O4 staining, such as scattered O4 staining
in their processes compared with control iPSC-derived
OLs,whichexhibiteduniformO4staining in their processes
(Figure 5A). Thus, to investigate the apoptotic processes of
PMD iPSC-derived OL lineage cells, we examined the
expression of cleaved caspase-3 (apoptotic marker) in O4+-
immature OLs andMBP+-mature OLs via immunostaining.
Some of the PMD iPSC-derived OLs that showed scattered
O4 staining in their processes were positive for cleaved cas-
pase-3 (Figure 5B). The numbers of cleaved caspase-3+ cells
in both PMD1 and PMD2 iPSC-derived immature OLs and
mature OLs were significantly increased compared with
those derived from control iPSCs (Figure 5C). We next per-
formed immunocytochemistry for KI67 and OLIG2. We
found that the proportion of OLIG2+ cells and KI67+ cells
among OLIG2+ cells were unchanged between PMD and
control samples, suggesting that the compensatory prolifer-
ation of OPCs for increased apoptosis in PMD iPSC-derived
OLs is unlikely (Figures S2A and S2B). Therefore, althoughistry of three neural lineage cells (neurons: bIII tubulin; astrocytes:
cells in control-iPSCs (201B7, WD39, and TIG121)-derived neuro-
m Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authors 653
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Figure 3. Differentiation Potential of Human iPSCs into
Oligodendrocytes
(A) Representative image of immunocytochemistry for OPC
markers (PDGFRa and NG2). OPCs were positive for both
PDGFRa and NG2. The scale bar represents 50 mm.
(B) Representative image of immunocytochemistry of
differentiated neurospheres using markers for OL lineage
cells. Both control and PMD iPSCs differentiated into
PDGFRa+-OL progenitor cells (OPCs), O4+-immature OLs
(immature OLs), and MBP+-mature OLs (mature OLs). The
scale bar represents 20 mm.
(C) Quantitative analysis of the differentiation efficiency
into OL lineage cells. The numbers of neurosphere colonies
containing more than 40 marker-positive cells (R40 cells;
oligodendrocyte [++]), those containing less than 40
marker-positive cells (1–39 cells oligodendrocyte [+]), and
those without marker-positive cells (oligodendrocyte [])
were counted and are presented as the percentage of total
neurosphere colonies. Oligodendrocyte (++) neurosphere
colonies and oligodendrocyte (+) neurosphere colonies are
indicated by black and white bars, respectively (PDGFRa, n =
6; O4, n = 6; MBP, n = 4; mean ± SEM; independent experi-
ments). No significant difference was detected among con-
trol (201B7, WD39, and TIG121) and PMD iPSCs (PMD1-7,
PMD1-15, and PMD1-27 and PMD2-6, PMD2-10, and PMD2-
22)-derived OL lineage cells (p > 0.05; Mann-Whitney’s
U test).
(D) Representative image of immunocytochemistry for
OLIG2, PDGFRa, and MBP after 2 or 4 weeks differentiation of
control-iPSC-derived second neurospheres containing more
than 40 OLIG2-positive cells. The scale bar represents 50 mm.
(E) Quantitative data of the percentages of PDGFRa+ cells/
OLIG2+ cells and MBP+ cells/OLIG2+ cells (after 2 or 4 weeks
of differentiation) in control-iPSC (201B7, WD39, and
TIG121)-derived neurospheres containing more than 40
OLIG2-positive cells. (n = 3; mean ± SEM; independent ex-
periments). After 2 and 4 weeks of differentiation, OLIG2+
and PDGFRa+ OPCs were abundantly observed. After 4 weeks
of differentiation, small numbers of MBP+ mature OLs
appeared.
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Figure 4. Involvement of ER Stress in
PMD-Derived Oligodendrocytes
(A) Representative immunocytochemistry
image for PLP1, the OL marker MBP, and the
ER marker KDEL. In the control iPSC-derived
mature OLs, the PLP1 protein localized to
both the ER (KDEL) and membrane, whereas
in the PMD iPSC-derived OLs, the mutant
PLP1 protein only localized to the ER. The
scale bar represents 20 mm.
(B) Three-dimensional image of mature OLs
derived from PMD1 iPSCs showing colocali-
zation of the mutant PLP1 protein and KDEL
via confocal laser scanning microscopy. The
scale bars represent 20 mm.
(C) Quantitative RT-PCR analyses of the
expression of ER stress markers in O4+ cells.
The data are presented as the expression
relative to that in iPSCs. No significant dif-
ferences were observed between the control
iPSC (201B7, WD39, and TIG121) and PMD
iPSC (PMD1-7, PMD1-15, and PMD1-27 and
PMD2-6, PMD2-10, and PMD2-22)-derived
cells (n = 5; mean ± SEM; independent ex-
periments; t test).
(D) Quantitative RT-PCR analyses of the
expression of ER stress markers in tunica-
mycin-treated (50 nM; 6 hr) O4+ cells relative
to untreated O4+ cells. A higher level of stress
susceptibility was detected in PMD1 (PMD1-
7, PMD1-15, and PMD1-27) than in control
(201B7, WD39, and TIG121) and PMD2
(PMD2-6, PMD2-10, and PMD2-22; n = 5;
mean ± SEM; independent experiments; *p <
0.05; **p < 0.01; Mann-Whitney’s U test).
(E) Quantitative RT-PCR analyses of the
expression of ER stress markers in tunica-
mycin-treated (100 nM; 6 hr) O4+ cells rela-
tive to untreated O4+ cells. PMD2 iPSC
(PMD2-6, PMD2-10, and PMD2-22)-derived
OLs showed significantly higher expression
levels of spliced XBP1 than control iPSC
(201B7, WD39, and TIG121)-derived OLs (n =
3; mean ± SEM; independent experiments;
*p < 0.05; t test).
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Modeling PMD by iPSC-Derived Oligodendrocytesthe differentiation efficiency into oligodendrocyte lineage
cells was unchanged between PMD and control (Figure 3C),
considering that anti-O4 and anti-MBP antibodies stain
both apoptotic and live OLs (Figures 5A and 5C), theSteincreased levels of apoptosis resulted in decreased numbers
of live OLs in PMD iPSC-derived cultures.
Because previous reports have indicated the neurotro-
phic actions of PLP1 (Griffiths et al., 1998; Yin et al.,m Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authors 655
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Figure 5. Enhanced Apoptosis in PMD
iPSC-Derived Oligodendrocytes
(A) Morphological differences in OLs. Immu-
nocytochemical analysis of iPSC-derived OLs
for OLs marker (O4) and nuclei (Hoechst). The
OLs showed a uniform appearance in the
control iPSC-derived cells but showed scat-
tered morphologies in the PMD iPSC-derived
cells. The scale bar represents 40 mm.
(B) Representative immunocytochemical
images of apoptotic OLs using markers for
apoptosis (cleaved caspase-3) and OLs (O4).
OLs (O4+ or MBP+) that were both positive
for cleaved caspase-3 and showed nuclear
condensation or fragmentation were consid-
ered apoptotic OLs. The scale bar represents
40 mm. c-caspase-3, cleaved caspase-3.
(C) Quantitative analysis of the number of
apoptotic OLs. The number of apoptotic cells
was higher in the PMD1 (PMD1-7, PMD1-15,
and PMD1-27) and PMD2 iPSC (PMD2-6,
PMD2-10, and PMD2-22)-derived OLs than
control iPSC (201B7, WD39, and TIG121)-
derived OLs (n = 9; mean ± SEM; independent
experiments; *p < 0.05; **p < 0.01; Mann-
Whitney’s U test).
Stem Cell Reports
Modeling PMD by iPSC-Derived Oligodendrocytes2006), we next investigated whether apoptosis was
induced in PMD patient-derived neurons. However, no
cleaved caspase-3+ neurons derived from either control or
PMD iPSCs were observed (Figure S2C), suggesting that
this increased apoptosis was specific to oligodendrocyte
lineage cells in PMD in our iPSC-derived cultures.
Abnormal Myelin Structures and ER Morphologies
Were Detected by Electron Microscopic Analysis
Finally, we focused on the myelinating properties of PMD
iPSC-derived OLs, which represent the most characteristic
pathogenic feature of PMD. Because different types of neu-
ral cells, including neurons and astrocytes, in addition to
OLs, were derived in our cultures, neuron-glial interactions656 Stem Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authorscould be observed and neuron myelination by the iPSC-
derived OLs could be analyzed in situ. In immunocyto-
chemical analysis of MBP and NF200 (neurofilament
marker), parts of the neurofilament+ neurites werewrapped
by theMBP+ process of iPSC-derived oligodendrocytes (Fig-
ure S3A). Thus, to evaluate the histological abnormality of
the myelin structures in vitro, we performed transmission
electron microscopy (TEM) analysis of ultrathin sections
of the differentiated cells. The results showed that myelin
structures with or without axons could be observed via
TEM. Considering the neuronal processes wrapped by
the MBP+ process of iPSC-derived OLs observed through
immunocytochemistry, some of the axonal structures
could have been lost during the fixation process for TEM.
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Figure 6. Electron Microscopic Analysis of
PMD iPSC-Derived Cells
(A) TEM of iPSC-derived cells. The maximum
number of normal myelin lamella was greater
than 30 in the control iPSC-derived myelin
sheaths. In contrast, a limited number of
myelin lamella was observed in the PMD iPSC-
derived myelin sheaths. High-magnification
images are also shown in the lower panel. The
scale bars represent 100 nm (upper panels)
and 20 nm (lower panels).
(B) Quantitative analysis of the numbers of
myelin structures. We counted the numbers
of myelin structures per visual field of EM
images (approximately 1.8 mm2) for the
myelination frequency. The frequency of
myelin formation was significantly decreased
in both PMD1 (PMD1-7, PMD1-15, and PMD1-
27) and PMD2 (PMD2-6, PMD2-10, and PMD2-
22) iPSC-derived OLs (n = 3; mean ± SEM;
independent experiments; *p < 0.05; t test).
(C) Quantitative analysis of the numbers of
myelin lamellae. We counted the numbers of
major dense lines per myelinated fiber for the
thickness of myelin, and the average of the
numbers of myelin lamellae in the top ten
myelin sheaths are presented. The thickness
of the myelin sheath was greatly reduced in
both PMD1 (PMD1-7, PMD1-15, and PMD1-
27) and PMD2 (PMD2-6, PMD2-10, and PMD2-
22) iPSC-derived OLs (n = 3; mean ± SEM;
independent experiments; **p < 0.01;
t test).
(D and E) Histological abnormalities de-
tected in PMD iPSC-derived cells via TEM.
Apoptotic cells with fragmented nuclei
(arrow in D) were frequently detected among
the PMD-iPSC-derived cells (D). The scale bar
represents 1 mm. Dilations of ER intermem-
brane spaces were also observed (E). The
scale bars represent 0.5 mm.
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Modeling PMD by iPSC-Derived OligodendrocytesAlthough we stained with antibodies against NAV1.6
(nodes) and CASPER (paranodes), we could not detect
any significant staining in our cultures. This may suggest
immature myelination in the present culture conditions.
Notably, mature myelin structures with thick myelin
lamella 30 layers were observed in the control cultures.
In contrast, in the PMD iPSC-derived cultures, a limited
number of myelin structures with thin myelin lamella
15 layers were observed (Figure 6A). The frequency of
myelin formation and thickness of the myelin sheath
were significantly decreased in both PMD1 and PMD2
iPSC-derived OLs (Figures 6B and 6C).SteIn addition, several types of histological abnormalities
were detected in the PMD cells. Apoptotic cells exhibiting
nuclear condensation were frequently observed among
the PMD iPSC-derived cells, in contrast to that observed
in those derived from control iPSCs (Figure 6D). More-
over, aberrant ER morphologies, such as dilation of the
ER intermembrane space (Fan et al., 2013; Lim et al.,
2011), were found in the PMD iPSC-derived cells (Fig-
ure 6E). These results indicate that PMD iPSC-derived
OLs develop a poor myelin structure and subsequently
die, supporting the involvement of ER stress in the path-
ogenesis of PMD.m Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authors 657
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In this study, we established PMD-specific human iPSCs
from two patients with different clinical severity and
different missense mutations of PLP1. One mutation is in
the transmembrane domain (PMD1) and the other is in
the extracellular domain (PMD2), both of which differ
from those in the previously reported PMD animal models.
And we generated patient-specific OLs. This model enables
an investigation of the correlations between the molecular
pathophysiology of PMD and various cell biological phe-
nomena, including OL differentiation, myelination, and
apoptosis in patient-derived live OLs through morpholog-
ical, biochemical, andmolecular biologicalmethods. These
analyses could not be achieved using conventional disease
models.
Although there are several reported methods for
inducing OPCs from human ESCs (Hu et al., 2009; Izrael
et al., 2007; Kang et al., 2007), these methods have diffi-
culties in reproducibility, making it difficult to obtain suffi-
cient amounts of mature OLs for analysis. In the present
study, we developed an improved neural differentiation
protocol for human pluripotent stem cells by utilizing an
EB-neurosphere method involving dual Smad inhibition
in combination with a GSK3 inhibitor to facilitate differen-
tiation into NS/PCs more efficiently and reproducibly. In
addition, the use of T3, ciliary neurotrophic factor
(CNTF), and leukemia inhibitory factor (LIF) was beneficial
for differentiation into OLs. Using this method, we
achieved stable differentiation of several human iPSC
clones into OLs in a similar manner to that reported in a
recent study (Wang et al., 2013). Remarkably, our culture
procedure enabled recapitulation of myelin formation in
human iPSC (hiPSC)-derived neurites and OLs in vitro in
a single-culture system without coculturing with other
cells, such as rodent hippocampal neurons, as previously
reported (Kang et al., 2007). Thus, this study reports a suc-
cessful in vitro myelination assay using human iPSC-
derived neurons and OLs.
Another important finding of this study was that the dif-
ferentiation of PMD iPSCs into OLs well-recapitulated the
progression of PMD pathogenesis in vitro. Although the
PMD-specific iPSCs induced abundant MBP+ mature OLs,
myelination was substantially less frequent and limited
lamella formation was observed. These results suggest
that incomplete maturation and limited survival of OLs
rather than a failure to differentiate into OLs is responsible
for PMD pathogenesis. However, the cause of OL degener-
ation and dysmyelination observed in PMD is unclear.
Some previous reports have demonstrated the involvement
of ER stress in the pathogenesis of PMD associated with
missense mutations in the PLP1 gene. Analyses using
cell lines, such as cos7 cells transfected with wild-type or658 Stem Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authorsmutant PLP1 genes, have shown that wild-type PLP1 pro-
tein is synthesized in the ER and transported to the cell sur-
face, whereas mutant PLP1 proteins are arrested in the
secretory pathway at an early stage and accumulate in the
ER (Gow et al., 1994). In the CNS of PMD model mice,
such asmsd and rshmice, mutant PLP1 proteins are largely
confined to the perinuclear region of OLs and involved in
the UPR (Gow et al., 1998). These reports suggest the
involvement of ER stress in PMD pathogenesis. In the pre-
sent study, accumulation of misfolded mutant PLP1 pro-
teins in the ER and high susceptibility to ER stresses in
the PMD1 and PMD2 cells were observed. This increased
susceptibility to ER stresses or other cellular response could
have resulted in the apoptosis of PMD iPSC-derived OLs
and immature/incomplete myelination.
In addition, we detected differences between PMD1 and
PMD2 cells. The differences of susceptibility to ER stresses
and the thickness of the myelin sheath were consistent
with the different levels of clinical severity of the two pa-
tients. The correlations between different clinical severity,
different missense mutations, and different pathogenic
changes have not previously been reported by conven-
tional disease models. These results suggest that this PMD
model accurately recapitulates disease pathophysiology
not only qualitatively but also in terms of the degree of
disease progression, although how the different point
mutations affect the degree of the observed phenotype
must be clarified. Accordingly, we propose models for a
‘‘proof-of-concept’’ of PMD pathogenesis based on the
endogenous mutations found in PMD iPSC-derived OLs.
The present findings cannot be generalized to PMD as a
whole because the more common PLP1 duplication was
not included; therefore, we will investigate the pathogen-
esis of PMD with PLP1 duplications in the future.
The current study represents the a demonstration of
pathogenic changes in PMD patients with PLP1 missense
mutations using disease-specific, human iPSC-derived
OLs. Thismodel faithfully reproduces the pathophysiology
observed in the CNS of PMD patients, which is difficult to
identify through conventional experiments. Moreover, our
results demonstrate the usefulness of iPSC-derived OLs for
the analysis of the pathogenic processes of dysmyelinating
human neurological disorders and the development of
novel therapeutic agents for their treatment.EXPERIMENTAL PROCEDURES
Isolation ofHuman Skin Fibroblasts andGeneration of
iPSCs
HDFs from the dermis of a 1-year-old Japanese male patient and
HDFs from the dermis of a 20-year-old Caucasian male patient
(Coriell Institute: GM09546) were used to establish PMD1-iPSCs
(PMD1-7, 1-15, and 1-27) and PMD2-iPSCs (PMD2-6, 2-10, and
Stem Cell Reports
Modeling PMD by iPSC-Derived Oligodendrocytes2-22), respectively. Additional control cell lines used in this study
included 201B7 (control A, established from HDFs [Cell Applica-
tions] from the dermis of a 36-year-old Caucasian female; Takaha-
shi et al., 2007), WD39 (control B, established from HDFs from
the dermis of a 16-year-old Japanese female; Imaizumi et al.,
2012), and TIG121 (control C, established from HDFs from the
dermis of an 8-month-old Japanese male [Japan Health Sciences
Foundation]). All of the human iPSC clones were established
through the retroviral transduction of four transcription factors
(SOX2, OCT4, KLF4, and c-MYC) into HDFs as described previ-
ously (Takahashi et al., 2007) and evaluated based on the expres-
sion of pluripotent markers, the silencing of retroviral transgenes,
and teratoma formation assays as described previously (Ohta
et al., 2011). We used three clones for each group for further anal-
ysis: control (201B7, WD39, and TIG121), PMD1 (1-7, 1-15, and
1-27), and PMD2 (2-6, 2-10, and 2-22). The data from the three
clones were combined in each figure, and the data are shown
as the average of the three clones. All of the experimental proce-
dures for iPSC production were approved by the ethics committee
of the Keio University School of Medicine (approval number: 20-
16-18).Culture and In Vitro Differentiation of Human iPSCs
hiPSCswere grown onmitomycin-C-treated SNLmurine fibroblast
feeder cells in gelatin-coated (0.1%) tissue culture dishes. The
hiPSCs were maintained in standard hESC medium (Dulbecco’s
modified Eagle’s medium [DMEM]/F12 [Sigma] containing 20%
KnockOut serum replacement [KSR; Life Technologies], nonessen-
tial amino acids [NEAA], 0.1 mM 2-mercaptoethanol [Sigma], and
4 ng/ml fibroblast growth factor 2 [FGF-2] [PeproTech]) at 37C in a
humidified atmosphere of 3% CO2.
For in vitro differentiation, iPSC colonieswere detached from the
feeder layers en bloc using a dissociation solution (0.25% trypsin,
100 mg/ml collagenase IV [Invitrogen], 1 mMCaCl2, and 20% KSR;
day 0) and cultured in suspension in bacteriological dishes to form
EBs in a humidified atmosphere of 3% CO2. From day 1 to 4 of EB
formation, 3 mM dorsomorphin (Sigma), 3 mM SB431542 (Tocris
Bioscience), and 3 mM BIO ((20Z, 30E)-6-bromoindirubin-30-oxime;
Sigma) were added. In addition, 1 mM retinoic acid (Sigma) and
1 mM purmorphamine (Calbiochem) were added on days 4 and
7, respectively, and maintained thereafter until day 16 (EB dissoci-
ation). The mediumwas changed every 2 days. On day 16, the EBs
were enzymatically dissociated into single cells using TrypLE Select
(Life Technologies), and the dissociated cells were cultured in sus-
pension at a density of 1 3 105 cells/ml in proliferation medium
consisting of serum-free medium (media hormone mix [MHM];
Okada et al., 2008) supplemented with 2% B27 supplement
(Invitrogen), NEAA, 1 mM purmorphamine, 60 ng/ml T3 (Sigma),
10 ng/ml PDGF-AA (PeproTech), 20 ng/ml FGF, 10 ng/ml
epidermal growth factor (PeproTech), 10 ng/ml insulin growth fac-
tor 1, and 10 ng/ml neurotrophin-3 (R&D Systems) in a humidified
atmosphere of 5% CO2. The mediumwas changed every 46 days
for approximately 1520 days to form the first neurospheres. To
passage neurospheres, the first neurospheres were dissociated in
the same manner as described above and cultured at a density of
13 105 cells/ml in proliferationmediumwithout purmorphamine
for approximately 1520 days. To assay neurosphere differentia-Stetion, undissociated 5–7 neurospheres were plated onto coverslips
10 mm in diameter coated with poly-L-ornithine (Sigma) and
growth-factor-reduced Matrigel (503 dilution, thin coated; Invi-
trogen), and cultured in differentiation medium that consisted of
MHM supplemented with 2% B27 supplement, NEAA, 60 ng/ml
T3, 10 ng/ml hLIF (Millipore), and 25 ng/ml CNTF (R&D Systems)
for 2–6 weeks in a humidified atmosphere of 5% CO2. Half of the
medium was changed every 2 or 3 days. For the quantitative
analysis of the differentiation efficiency into OL lineage cells,
the numbers of neurosphere colonies containing more than 40
marker-positive cells (R40 cells, oligodendrocyte [++]), those con-
taining less than 40 marker-positive cells (1–39 cells, oligodendro-
cyte [+]), and those withoutmarker-positive cells (oligodendrocyte
[]) were counted and are presented as the percentage of total neu-
rosphere colonies. To examine the expression of ER-stress markers,
O4+ differentiated cells were purified 4 weeks after the attachment
of the neurospheres using MACS technology with an anti-O4
antibody.Direct Sequencing and Pyrosequencing Analysis of the
PLP1 Gene
Genomic DNA was extracted from peripheral blood samples (leu-
kocytes) from PMD1 and from HDFs and iPSCs from both PMD1
and PMD2. For direct sequencing of the mutations in the PLP1
gene in PMD1, fragments of the promoter regions (50 UTR)
and all seven exons of the PLP1 gene were amplified via PCR.
The PCR primers and cycling conditions employed for direct
sequencing are listed in Table S1. For pyrosequencing analysis of
themutations in the PLP1 gene in HDFs and iPSCs, fragments con-
taining the PMD1mutation (c.757 T > A in exon 6) and PMD2mu-
tation (c.643C > T in exon 5) were amplified via PCR using forward
primers and biotinylated reverse primers. Pyrosequencing analyses
were performed following the manufacturer’s instructions (Pyro-
mark Q24; QIAGEN). The PCR primers and cycling conditions
applied for pyrosequencing analysis are listed in Table S2.RNA Isolation and RT-PCR
RNA isolation and real-time quantitative RT-PCR were performed
as previously described using SYBR Premix ExTaq II and the
MX3000P Real-Time PCR system (Stratagene; Okada et al., 2004,
2008). The amount of cDNAwas normalized to that of human-spe-
cific b-ACTINmRNA.
For the analysis of the expression of retroviral transgene in iPSCs,
HDFs 7 days after the retroviral introduction (day 11 of the proto-
col) of four genes (SOX2,OCT4, KLF4, and c-MYC) were used as the
positive control (SOX2 tg, OCT4 tg, KLF4 tg, and c-MYC tg). The
data are presented as the copy numbers of mRNA for each trans-
gene. As for the analyses of NANOG, SOX1, BRACHYURY, SOX17,
bIII tubulin,GFAP,CNP, and ER stressmarker (BIP,CHOP, and spliced
XBP1), data are presented as the relative expression to that in con-
trol. The applied primer sequences and PCR cycling conditions are
listed in Table S3.Immunocytochemical Analysis
For immunocytochemical analysis, cells were fixed with 4% para-
formaldehyde for 30 min at room temperature. After blocking inm Cell Reports j Vol. 2 j 648–661 j May 6, 2014 j ª2014 The Authors 659
Stem Cell Reports
Modeling PMD by iPSC-Derived Oligodendrocytesblocking buffer (PBS containing 10%normal goat or donkey serum
and 0.3%TritonX-100) for 1 hr at room temperature, the cells were
incubated with primary antibodies at 4C overnight. For O4 stain-
ing, we used blocking buffer without Triton X-100. After three
washes with PBS, the cells were incubated with Alexa 488-, Alexa
555-, or Alexa 647-conjugated secondary antibodies (Life Technol-
ogies) for 1 hr at RT. Nuclei were stained with 10 mg/ml Hoechst
33258 (Sigma). After washing with PBS, the cells were mounted
on slides and examined with a universal fluorescence microscope
(Axiophoto; Carl Zeiss) or confocal laser scanning microscope
(LSM700; Carl Zeiss). The primary antibodies used in these ana-
lyses were as follows: NANOG (1:100; ReproCELL), OCT4 (1:500;
Santa Cruz Biotechnology), OLIG2 (1:1,000; R&D Systems),
PDGFRa (1:2,000; Santa Cruz Biotechnology), NG2 (1:2,000; Milli-
pore), O4 (1:5,000;Millipore), MBP (1:1,000; Serotec), b-III-tubulin
(1:1,000; Sigma), NF200 (1:1,000, Millipore), GFAP (1:4,000,
Dako), KDEL (Abcam), PLP1 (1:30,000; gifted from Masayuki
Itoh [National Center of Neurology and Psychiatry] recognizes
PLP1, but not DM20), KI67 (1:10,000, Abcam), and cleaved caspase
3 (1:1,000, Cell Signaling Technology).Teratoma Assay
Undifferentiated iPSCs (5 3 105 cells) were injected into the
testes of 8-week-old male nonobese diabetic (NOD)/severe com-
bined immunodeficiency (SCID) mice (Charles River Labora-
tories) as described previously (Ohta et al., 2011). Eight weeks
after injection, the resultant tumors were dissected and fixed
with 4% paraformaldehyde. Paraffin-embedded tissue sections
were produced, and hematoxylin and eosin (H&E) staining was
performed. Images were obtained using a BZ-9000 microscope
(Keyence).Transmission Electron Microscopy
For TEM analysis, neurospheres and cells in dishes were fixed
with 2.5% glutaraldehyde in 50 mM phosphate buffer (PB) over-
night at 4C. After washing twice in 0.1 M PB, these samples fixed
with 1% osmium tetroxide for 90 min, dehydrated through
ethanol, and embedded in Epon. The neurospheres were
dissected and fixed on the stage, followed by the preparation of
ultrathin sections with a thickness of 70 nm using an ultramicro-
tome (Leica Microsystems). The sections were subsequently
stained with uranyl acetate and lead citrate for 10 and 12 min,
respectively. Finally, the sections were observed under a transmis-
sion electron microscope (JEOL model 1230), and images were
captured with Digital Micrograph 3.3 (Gatan). For the quantita-
tive analysis of myelination, the number of myelin lamellae,
which is the number of major dense lines per myelinated fibers,
was counted to assess myelin thickness and the number of
myelinated fibers per visual field of electron microscopy (EM) im-
ages (approximately 1.8 mm2) was counted to assess myelination
frequency.
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